focus -WSS

focus

author：focus 2025-10-01 07:41:09 - browse：55

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

hotspot

focus

WSS

Adele warns fans about throwing things at performers onstage

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

For Medicare Advantage, Democrats want stronger protections around AI

Doctors' information doesn't help them choose wisely when sick

BioAge raises $170M for combination therapy with Zepbound

EU moves toward latest gene techniques in food production to counter climate change, shortages

hotspot

focus

entertainment

Affirmative action in medical school literally saved lives

Search warrant issued in 1996 disappearance of Kristin Smart

The high cost of giving birth even with insurance

Private equity deals in Medicare Advantage declines

Medical records are filled with copy

Biden report: The neurospychology of memory and aging

Dobbs anniversary: the lost opportunity of abortion as health care

Robert F. Kennedy is pitching centrism on health, even on abortion

Psychedelics group wrestles with new pharma identity

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

leisure time

China dismisses criticism of top diplomat's comments appearing to push for race

Adele warns fans about throwing things at performers onstage

How digital tools helped lower hypertension in marginalized patients

How digital tools helped lower hypertension in marginalized patients

Biden report: The neurospychology of memory and aging

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

hotspot

knowledge

focus

hotspot